A collage photo of Paolo Tarantino and Albert Grinshpun
Feb 18, 2024, 10:00
Paolo Tarantino: How do SONIA and NATALEE impact our use of CDK4/6-inhibitors
Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:
“How do SONIA and NATALEE impact our use of CDK4/6-inhibitors? Should they still be given 1L? And are we ready for adjuvant ribociclib? Glad to join my friend and former co-fellow Albert Grinshpun for reviewing updates in the CDK4/6i field on ASCO Daily News.”
Additional information.
Source: Paolo Tarantino/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14